This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Iptacopan
- DrugBank Accession Number
- DB16200
- Background
Iptacopan is under investigation in clinical trial NCT04578834 (Study of Efficacy and Safety of LNP023 in Primary Iga Nephropathy Patients).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Iptacopan (DB16200)
- Weight
- Average: 422.525
Monoisotopic: 422.220557454 - Chemical Formula
- C25H30N2O4
- Synonyms
- Iptacopan
- External IDs
- LNP-023
- LNP023
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8E05T07Z6W
- CAS number
- 1644670-37-0
- InChI Key
- RENRQMCACQEWFC-UGKGYDQZSA-N
- InChI
- InChI=1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1
- IUPAC Name
- 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid
- SMILES
- CCO[C@H]1CCN(CC2=C(OC)C=C(C)C3=C2C=CN3)[C@@H](C1)C1=CC=C(C=C1)C(O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 75533872
- ZINC
- ZINC000223246892
- PDBe Ligand
- JGQ
- PDB Entries
- 6rav
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Paroxysmal Nocturnal Haemoglobinuria (PNH) 2 3 Not Yet Recruiting Treatment Paroxysmal Nocturnal Haemoglobinuria (PNH) 1 3 Recruiting Treatment Atypical Hemolytic Uremic Syndrome (aHUS) 1 3 Recruiting Treatment C3G 1 3 Recruiting Treatment IgA Nephropathy (IgAN) 1 3 Recruiting Treatment Paroxysmal Nocturnal Haemoglobinuria (PNH) 1 3 Recruiting Treatment Primary IgA Nephropathy 1 2 Active Not Recruiting Treatment Glomerulonephritis, Membranous 1 2 Completed Treatment Glomerulonephritis 1 2 Completed Treatment IgA Nephropathy (IgAN) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00578 mg/mL ALOGPS logP 4.08 ALOGPS logP 1.4 Chemaxon logS -4.9 ALOGPS pKa (Strongest Acidic) 3.7 Chemaxon pKa (Strongest Basic) 8.75 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 74.79 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 121.95 m3·mol-1 Chemaxon Polarizability 47.52 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 15, 2020 18:15 / Updated at February 21, 2021 18:55